Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_000548.5(TSC2):c.648+6T>C variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000558 in 1,613,936 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
TSC2 (HGNC:12363): (TSC complex subunit 2) This gene is a tumor suppressor gene that encodes the growth inhibitory protein tuberin. Tuberin interacts with hamartin to form the TSC protein complex which functions in the control of cell growth. This TSC protein complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]
Computational evidence support a benign effect (BayesDel_noAF=-0.54).
BP6
Variant 16-2056250-T-C is Benign according to our data. Variant chr16-2056250-T-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 452900.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=2, Uncertain_significance=1}.
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Jan 29, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
not provided Uncertain:1
Oct 19, 2017
GeneDx
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing
A variant of uncertain significance has been identified in the TSC2 gene. The c.648+6 T>C varianthas not been published as a pathogenic variant, nor has it been reported as a benign variant to ourknowledge. The c.648+6 T>C variant is observed in 4/24,028 (0.02%) alleles from individuals ofAfrican background (Lek et al., 2016). This substitution occurs at a position that is conserved acrossspecies. Several in-silico splice prediction models predict that c.648+6 T>C may damage the natural splice donor site in intron 7 and lead to abnormal gene splicing. However, in the absence ofRNA/functional studies, the actual effect of this sequence change in this individual is unknown.Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. -
TSC2-related disorder Benign:1
Mar 30, 2022
PreventionGenetics, part of Exact Sciences
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -